Abcellera Biologics On Sept 18 Took Ownership Of Antibody Drug Candidate That Was Discovered By Co As Part Of Its Collaboration With EQRX; Advancing Antibody Drug Candidate Into Ind-enabling Studies
Portfolio Pulse from Charles Gross
Abcellera Biologics has taken ownership of an antibody drug candidate that was discovered as part of its collaboration with EQRX. The company is now advancing the drug candidate into IND-enabling studies.
October 13, 2023 | 10:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abcellera Biologics has acquired an antibody drug candidate from its collaboration with EQRX, which it is now advancing into IND-enabling studies. This could potentially lead to a new product offering.
The acquisition of the antibody drug candidate and its advancement into IND-enabling studies indicates that Abcellera Biologics is making progress in its product development. This could potentially lead to a new product offering, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100